Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma

Obinutuzumab (G) chemoimmunotherapy demonstrated improved progression-free survival (PFS) vs rituximab-based chemoimmunotherapy in patients with previously untreated follicular lymphoma (FL) in the GALLIUM trial. Atezolizumab (atezo) is a programmed death-ligand 1 inhibitor with a complementary mech...

Descripción completa

Detalles Bibliográficos
Autores principales: Younes, Anas, Burke, John M., Diefenbach, Catherine, Ferrari, Silvia, Khan, Cyrus, Sharman, Jeff P., Tani, Monica, Ujjani, Chaitra, Vitolo, Umberto, Yuen, Sam, Raval, Aparna, Shivhare, Mahesh, Nielsen, Tina G., Sellam, Gila, Gilbertson, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582582/
https://www.ncbi.nlm.nih.gov/pubmed/35359000
http://dx.doi.org/10.1182/bloodadvances.2021006131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582582/
https://www.ncbi.nlm.nih.gov/pubmed/35359000
http://dx.doi.org/10.1182/bloodadvances.2021006131

Ejemplares similares